Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + axitinib
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Crizotinib + axitinib is a combination of two small molecule tyrosine kinase inhibitors investigated for the treatment of advanced solid tumors, including metastatic renal cell carcinoma (mRCC). Crizotinib inhibits multiple receptor tyrosine kinases, primarily anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR/c-MET), ROS1, and Recepteur d'Origine Nantais (RON), thereby blocking oncogenic signaling pathways that drive tumor proliferation and survival. Axitinib selectively inhibits vascular endothelial growth factor receptors 1–3 (VEGFR-1, VEGFR-2, VEGFR-3), suppressing angiogenesis and tumor growth. The combination aims to provide greater clinical benefit by targeting both angiogenesis and oncogenic signaling. Clinical studies have shown the combination has a manageable safety profile with evidence of antitumor activity in mRCC[1][3][4][5][6].
- Other names
- crizotinib + axitinib
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)MST1R (Recepteur d'origine nantais)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on crizotinib + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + axitinib.